Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

Inclusion Criteria:

Chronic scalp psoriasis for at least the previous six months
Moderate to severe scalp psoriasis as defined by a PSSI score of ≥12 and 30% or higher of scalp surface area affected
Must be candidates for systemic therapy, which means having scalp psoriasis inadequately controlled by topical treatments (corticosteroids), and/or phototherapy, and/or previous systemic therapy.

Exclusion Criteria:

Forms of psoriasis other than chronic plaque
Drug-induced psoriasis (e.g., new onset or current exacerbation from β-blockers, calcium channel inhibitors)
Ongoing use of prohibited treatments (e.g., topical or systemic corticosteroids, UV therapy)
Prior exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL17A or IL-17RA receptors
Use of other investigational drugs within 30 days prior to study entry, or within a period of 5 half-lives of the investigational treatment, whichever is longer
Active, ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of secukinumab
Active system infections (with the exception of the common cold) during the two weeks prior to starting study treatment
Other protocol-defined inclusion/exclusion criteria may apply